Shire sees strong product sales in first quarter
Pharmaceuticals group Shire has reiterated its expectation of good earnings growth in 2012 after a solid first-quarter performance, with total revenues rising by over a fifth on last year.
Pharmaceuticals group Shire has reiterated its expectation of good earnings growth in 2012 after a solid first-quarter performance, with total revenues rising by over a fifth on last year.
Total revenues in the three months to March 31st jumped by 21% to $1,172m, from $972m in the same period of 2011. Consensus forecasts were for group revenue of $1,148m. Product sales, which account for the majority of group revenues, increased by 24%.
Shire said that growth was driven particularly by sales of VYVANSE (up 29% to $260m), REPLAGAL (up 28% to $134m), ELAPRASE (up 21% to $126m), VPRIV (up 22% to $72m), FIRAZYR (up 272% to $20m) and INTUNIV (up 63% to $69m). First-quarter revenues also include a $49m contribution from DERMAGRAFT (Q1 2011: $nil) which was acquired with Advanced BioHealing in the second quarter of 2011.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"Shire continues to perform strongly with first quarter results in line with our expectations. [...] Our focus on demonstrating value to the healthcare system through meeting the needs of our patients is continuing to deliver," said Chief Executive Officer Angus Russell.
However, adjusted operating profits came in at $362m, up 18% year-on-year but slightly under the consensus forecast of $366m. Shire said that operating expenses increased at a faster rate than total revenues.
"Having made a strong start to the year, we reiterate our confidence in good earnings growth for 2012, while investing in our business to support sustained future growth."
The group expects full-year product sales growth to moderate to the mid-teens range. "Combining this with lower royalties and other revenues, which are expected to be 15% to 25% lower year on year, we are forecasting revenue growth in the low-teens range."
Shares were trading 1.05% higher at 2,023p by 13:15 in London.
BC
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Michelin Key Hotels 2025: the top destinations in the world
The Michelin Keys have been awarded to spectacular hotels across the world. From Marlon Brando's private resort in Polynesia to a Bvlgari hotel in Tokyo, we look at some of the most extraordinary stays in 2025
-
MoneyWeek news quiz: How much could you get in car finance compensation?
The car finance scandal, inheritance tax, and house prices all made headlines over the past few days. Test your knowledge while reviewing this week’s top stories with MoneyWeek’s news quiz